Navigation Links
Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010
Date:2/10/2011

consideration adjustment

6,519

(4)

-Restructuring charges

9,704

(5)

13,825

(5)Impairment charge

-7,080

(6)Acquired in-process research and development adjustments

100,000

(7)

46,118

(7)Interest expense adjustment

65,485

(8)

57,766

(8)Change in fair value of investments adjustment

(7,931)

(9)

-Other (income) expense adjustment

3,045

(10)

(40,011)

(10)Arana noncontrolling interest adjustments

-(819)

(11)Income tax adjustment

(122,784)

(12)

(89,979)

(12)*Noncontrolling Interest adjustments:Impairment charge

-175,000Other revenue

(276)19Research and development

6,40332,659Selling, general and administrative3,9948,784Restructuring charges

1,014-Interest income

(29)(187)Interest expense

1541,396Other expense

16633Impairment charge tax benefit

-(74,235)Income taxes

(4,852)(12,600)Less amount attributable to noncontrolling interest

(6,574)(130,869)231,281126,359ADJUSTED NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 657,026$ 468,986BASIC ADJUSTED INCOME PER COMMON SHARE

$
8.74$
.48DILUTED ADJUSTED INCOME PER COMMON SHARE

$
8.14$
.03WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING

75,18572,342WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING-ASSUMING DILUTION

80,71277,733* Amounts recorded by our Variable Interest Entities that have been excluded from net income attributable to Cephalon, Inc.Notes to Reconciliation of GAAP Net Income to Adjusted Net Income(1) To exclude the on-going amortization of acquired intangible assets ($119.7M in 2010; $97.5M in 2009), accelerated depreciation related to restructuring ($15.1M in 2010; $19.0M in 2009), amortization of inventory revaluation related to Mepha GmbH ($10.5M in 2010) and the reserve for modafinil pur
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Cephalon Signs Option Agreement to Acquire Assets from Alba Therapeutics
2. ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology
3. Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated With Jet Lag Disorder
4. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
5. Cephalon to Webcast Investor Day
6. Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
7. Cephalon Signs Investment Agreement to Fund ChemGenex Oncology Clinical Development Operations
8. Cephalon Exercises its Option to Acquire BioAssets Development Corporation
9. Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL
10. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
11. Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Kannalife Sciences, Inc. ("Kannalife") ... joined its Scientific Advisory Board to assist the Company ... towards the use of cannabinoid therapeutics for the treatment ... forensic pathologist responsible for conducting the full autopsy of ... Fame center for the Pittsburgh Steelers. It was through ...
(Date:3/4/2015)... March 4, 2015  Halyard Health, Inc. (NYSE: ... provided its 2015 outlook and related key planning assumptions. ... Health as we report our fourth quarter results, our ... and CEO. "We executed a smooth separation from Kimberly-Clark ... spin-off. We delivered sales growth and margin improvement in ...
(Date:3/4/2015)... March 4, 2015  ECR Booth #317/Expo C - ... showcasing a full spectrum of X-ray imaging solutions that ... costs, and enable greater patient throughput for manufacturers of ... These solutions are on display at the Annual European ... Austria this week.   "This ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 2Varian Medical Systems to Showcase New X-Ray Imaging Components at the European Congress of Radiology (ECR) Annual Meeting 3
... UPI ), a medical device company ... to treat voiding dysfunctions, announced today that David ... President and CFO, will present the Company,s business ... 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Medical ...
... 2011 Merrimack Pharmaceuticals, Inc. announced today that the ... clinical study combining MM-121, a fully human monoclonal antibody ... regimens for patients with advanced solid tumors. ... study evaluates the safety and pharmacokinetics of MM-121 when ...
Cached Medicine Technology:Uroplasty to Present at the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Medical Device Conference 2
(Date:3/5/2015)... Salt Lake City,Utah (PRWEB) March 05, 2015 ... that manufactures microFET medical dynamometers, ergoFET physical ... acquisition systems with sensors for ergonomics, engineering, ... new microFET Digital Handgrip Dynamometer, available at ... Handgrip was designed to offer healthcare professionals ...
(Date:3/5/2015)... Saint John, New Brunswick (PRWEB) March 05, 2015 ... board to help validate product innovations as the company ... advisory board will be comprised of individuals in the ... approach to working with our clients,” said Elandas CEO ... to grow as a successful organization through our collaborative ...
(Date:3/4/2015)... The emergence of nanotechnology has ... past decade. The pharmaceutical world has witnessed advancements ... the form of liposomes and polymeric nanoparticles that ... safety and efficiency. In the area of ... upon the enhanced permeability and retention (EPR) effect ...
(Date:3/4/2015)... Ultraman Florida is a grueling extreme athletic ... bike, and 52.4 mile run. Christian Isakson finished in ... "This race was awesome and tough," Isakson said. "I ... for supporting me through every part of this brutal ... of 40 select participants invited from across the United ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 TROY Healthcare ... software, which provides the ultimate level of security for ... the Hilton Houston Plaza Medical Center located at 6633 ... , Beginning at 7 AM, TROY Healthcare Solutions will ... Healthcare Solutions will offer brief presentations each hour to ...
Breaking Medicine News(10 mins):Health News:New Handgrip Strength Tester Receives Rave Reviews At Physical Therapy Conference 2Health News:Elandas Creates Advisory Board to Help Guide Innovation 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 2Health News:Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com 3Health News:Living Fuel Champion Christian Isakson Finishes Second In UltraMan Florida Test of Endurance 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3
... be detected earlier using a computer-assisted detection system ( ... a computer-based analysis designed to find breast abnormalities. // ... as tiny white specks on mammography film. These tiny ... reviewed the cases of 519 patients with breast cancer. ...
... second-leading cause of cancer death in men and kills nearly ... one in six, is higher than the one in eight ... shows the rate of rise in prostate-specific antigen levels, or ... indicator of eventual death from prostate cancer than the actual ...
... saying that the gene known as “mighty mouse” might ... gene arose when a German neurologist , stumbled // on ... tests revealed the child had a mutation in his myostatin ... protein, which is known to regulate muscle growth. So far ...
... New research shows a significant improvement in treatment for a ... I seminoma is typically treated by // removal of the ... developing a second cancer in another organ up to 20 ... receive a single course of the drug carboplatin and more ...
... found to boost the immune system and help fight off ... on children already in the hospital with severe pneumonia// and ... children with severe pneumonia recover quicker . ,The study ... About half received 20 milligrams of zinc per day while ...
... for cosmetic purposes to erase the signs of aging. However ... toxin is being used to treat a chronic condition known ... of the stomach after a meal. It may be for ... by the patient.The condition causes a person to feel full ...
Cached Medicine News:
The cardiac blanket is pre-positioned at the waist during prep, unrolled upon closure of the saphenous vein graft incision, and inflated post-bypass....
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Medicine Products: